ArticleInfection2026
Duration of protective effect after benzathine penicillin G prophylaxis for recurrent cellulitis: a 14-day window of efficacy.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFollowing the administration of prophylactic intramuscular benzathine penicillin G (BPG) for recurrent cellulitis, the precise duration of its protective effect remains unclear. We aimed to evaluate the prophylactic efficacy of BPG against recurrent cellulitis under various assumed durations of prophylaxis.
methodsThis retrospective observational study included 73 patients who received BPG prophylaxis for cellulitis. We compared cellulitis episodes between the prophylaxis and non-prophylaxis periods, and analyzed the timing of recurrence after BPG administration. A multivariable time-varying Cox regression analysis was performed, with time after BPG injection as the time-varying covariate.
resultsAn analysis of 592 patient-years revealed 310 recurrences. Under the assumption of a 14-day prophylactic window after BPG administration, the recurrence rate was significantly lower during the prophylaxis period than during the non-prophylaxis period (incidence rate ratio [IRR], 0.57; 95% confidence interval [CI], 0.33-0.99; P = .045). In contrast, when assuming prophylactic windows of 21 and 28 days, the IRRs were 0.74 (P= .154) and 0.92 (P= .642), respectively. Among the cellulitis episodes that occurred within 10 weeks of BPG administration, 43% occurred between days 15 and 28. After adjusting for lymphedema, the risk of recurrence was significantly lower within 14 days of BPG administration (adjusted hazard ratio, 0.54; 95% CI, 0.31-0.94; P= .030).
conclusionThe protective effect of intramuscular BPG against recurrent cellulitis was most pronounced during the first two weeks after administration, supporting the potential utility of individualized, shorter dosing intervals.
Indexed as
Identifiers
42848179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.